Multidrug-resistant tuberculosis (MDR-TB) is a particular threat to the populations of resourcelimited countries. Although inadequate treatment of TB has been identified as a major underlying cause of drug resistance, essential information to inform changes in health service delivery and policy is missing. We investigate factors that may be driving the emergence of MDR-TB in Myanmar, a country where investment and health system reforms are ongoing to address the unexplained, high occurrence of MDR-TB. We conducted a multi-centre, retrospective case-control study in 10 townships across Yangon. Cases were 202 GeneXpert-confirmed MDR-TB patients with a history of prior first-line treatment for TB. Controls were 404 previously untreated smear-microscopy confirmed TB patients who had no evidence of resistance to anti-TB drugs. Information on patient and health service factors was collected through face-to-face patient interviews and hospital record reviews. Multivariable logistic regression analysis indicated that the following TB patient groups are at higher risk of developing MDR-TB after initial TB treatment: those who have diabetes (aOR 2.10; 95% CI 1.17-3.76), those who missed taking drugs during the initial treatment more than once weekly (aOR 2.35; 95% CI 1.18-4.65) and those with a higher socioeconomic (aOR 1.99; 95% CI 1.09-3.63) or educational status (aOR 1.78; 95% CI1.01-3.13). Coinciding with a surge in funding to improve health in Myanmar, this study identifies practices of patients and healthcare organizations that can be addressed, and high-risk TB patient groups that can be prioritized for treatment support. Specifically, the study shows that TB patients who experience frequent, short interruptions in treatment and those with diabetes may require enhanced treatment support and monitoring by health services in order to prevent further generation of drug resistance.
Introduction
The rise in antimicrobial resistance is largely caused by improper practices around the use of antimicrobial drugs, and therefore requires combative measure to be implemented at the clinical, health system and policy level (Laxminarayan et al. 2013) . Drug resistance is a particular challenge for tuberculosis (TB) control; the emergence of 480 000 new multidrug-resistant tuberculosis (MDR-TB) cases every year is threatening to reverse progress made in recent decades. MDR-TB, which is defined as TB resistant to at least isoniazid and rifampicin, the two most powerful anti-TB drugs (WHO 2016) , is a result of inadequate treatment of patients infected with drugsensitive strains of TB and subsequent transmission of these strains. There is a concern that transitioning health systems, such as that of Myanmar, are more likely to promote the generation of drug resistance, and have less capacity to diagnose and manage drug-resistant cases when they arise (Parry 2009 ).
This study focuses on acquired or secondary resistance, referring to that fact that bacterial resistance develops during (inadequate) treatment with anti-TB drugs. In contrast, primary MDR-TB occurs owing to infection with a drug-resistant strain in patients who have not been treated for TB (Twisselmann 2000) . Although 'inadequate treatment' is identified as a major underlying cause of acquired resistance (Espinal et al. 2001; Faustini et al. 2006) , information about how and why inadequate treatment occurs in TB patients-which is essential to inform changes in health service delivery and policy-is missing (Cars et al. 2008) . For example, there is little evidence about whether the main driver of MDR-TB in patients previously treated for TB is poor compliance by the patient, inappropriate medication from healthcare providers or lack of guidance and support during treatment. Studies indicate that all of these factors play a role (Espinal et al. 2001; Ejaz et al. 2010; Kim et al. 2011 ), but their relative contributions are not well characterized. The role of other potential drivers of acquired resistance during TB treatment, such as compromised immunity of the patient, cavitation in lungs and smoking, also needs further investigation (Espinal et al. 2001; Faustini et al. 2006) .
It is increasingly recognized that MDR-TB may be growing in Asian countries with fragile health systems and an active, unregulated private health sector and that specific risk factors operating at the individual and health system level must be identified urgently to inform MDR-TB control strategies (Gandhi et al. 2010; Nair et al. 2010) . The aim of this study is to identify risk factors for the development of MDR-TB in Myanmar-a country with an unexplained, high prevalence of MDR-TB and a transitioning health system. The World Health Organization (WHO) estimates that 9000 MDR-TB cases occur in Myanmar each year and extensively drug-resistant TB (XDR-TB) has been reported since 2007 (WHO 2012) . The most recent WHO report classifies Myanmar as a country with a high TB, MDR-TB and HIV-TB burden. Acquired MDR-TB is estimated to occur in 27% of previously treated TB cases in Myanmar; this is considerably higher than other countries in South East Asia, such as Cambodia (11%) and Thailand (19%) (WHO 2014) . Despite these statistics, there is a dearth of research on determinants of MDR-TB in Myanmar, and a recent literature review concluded that there is a critical gap in evidence about drivers of drug resistance (Khan et al. 2016) . Among the limited literature available, a cross-sectional prevalence study on MDR-TB conducted in 2002 highlighted that inappropriate management of TB, possibly related to unregulated private health providers, is a concern (Ti et al. 2006) . A more recent phenotypic and genotypic analysis of MDR-TB in the two major cities-Yangon and Mandalay-indicated that the burden of MDR-TB might be even higher than estimated by previous studies (Aung et al. 2015) .
This study addresses the gap in evidence to inform improvements in healthcare practices and policies for the prevention of MDR-TB in Myanmar and the wider region by investigating factors that increase the risk MDR-TB developing in patients treated for TB.
Methods

Study setting
We conducted a case-control study in Yangon Division, Myanmar's main urban centre with a population of 7.4 million. Similar to the rest of Myanmar, health care and medical services in Yangon are provided by a combination of the public and private sector. The private sector, which is often the first port of call for symptomatic TB patients, includes various individuals and institutions, including international and local non-government organizations (NGOs), forprofit general practitioner (GP) clinics, for-profit hospitals, pharmacies, drug shops and traditional practitioners. GPs can be medically trained or untrained individuals posing as doctors. They include physicians who are employed in government service but who take private patients outside of office hours, and GPs engaged only in private practice (Saw et al. 2009 ). Studies in Myanmar have shown that private providers often diagnose and treat TB patients without following guidelines on management are reporting (Lö nnroth et al. 2007; Saw et al. 2009 ). The national Ministry of Health is responsible for the management of the public sector services and the National TB Programme (NTP) oversees TB control activities.
Public sector TB control activities are implemented through Yangon's Township Health Departments (THDs), which function as the main health facilities providing primary health care services and as a focal point for TB diagnosis, case registration and treatment provision (MOH 2012) . Where microscopy services are not available at THDs, sputum samples are sent to district or regional centres for diagnosis (Saw et al. 2009 ). However, patients are registered for treatment at their local THD. Patients can also be diagnosed and treated through one of the NTP's partner private organisations
Key Messages
• Although inadequate treatment with antimicrobial drugs is identified as the major cause of drug resistance, there is limited evidence about how and why inadequate treatment occurs, particularly in transitioning health systems.
• Our case-control study on risk factors for developing multi-drug resistant TB in Myanmar identified high-risk groupsincluding patients with diabetes and those who experience frequent, short interruptions in anti-TB treatment-that could be prioritized for enhanced treatment support and monitoring by health services in order to prevent generation of drug resistance.
operating under the Public Private Mix (PPM) initiative, such as the Myanmar Medical Association (MMA) and Population Services International (PSI); information about the diagnosis and treatment of patients treated by partner private health organizations is reported through the THDs according to a standardized reporting protocol. The PPM initiative allows providers to be involved in one of three schemes, ranging from referral of suspected TB cases to government centres for diagnosis and treatment to provision of free treatment to NTP-confirmed TB cases themselves using drugs provided by the NTP. Diagnostic and treatment protocols followed in line with those applied in public sector THDs; patients are either referred to THDs or NTP-approved private labs for microscopy and GeneXpert testing. At the time of the study, MDR-TB diagnosis and treatment was available at 68 townships across Myanmar, 44 of which are in Yangon Division. Diagnosis is based on the Xpert MTB/RIF test (GeneXpert) for resistance to rifampicin, which is used as a proxy for MDR-TB. Sputum culture and drug sensitivity testing are no longer used for confirmation of MDR-TB diagnosis following GeneXpert testing, although they are conducted monthly to monitor response to treatment (WHO 2013) . New MDR-TB cases are defined as patients with no prior history of TB treatment, while retreatment cases are those who are returning after loss to followup, those who have relapsed, recurred or have failed treatment (Category I or II). According to current guidelines in Myanmar, GeneXpert testing is indicated for the following patient groups thought to be at higher risk of MDR-TB: all previously treated TB patients (retreatment cases), patients on first-line drugs that are still smear-positive 3 months into treatment, TB patients with HIV and close contacts of MDR-TB patients (Myint 2015) . In addition, since NTP surveys have indicated a particularly high prevalence of MDR-TB in Yangon (unpublished data), all smear-positive TB patients diagnosed in Yangon are tested using GeneXpert.
Selection of cases and controls
We recruited patients from ten THDs across Yangon. All THDs were diagnosing TB and MDR-TB according to the national guidelines described earlier, and providing free treatment. The research team screened hospital records of all patients diagnosed between September 2014 and March 2015 in order to determine eligibility as detailed below; patients were recruited 3 months after their diagnosis had been confirmed.
We defined cases as adult patients with GeneXpert-confirmed MDR-TB and a recorded history of prior first-line treatment for pulmonary TB (referred to as previously treated MDR-TB patients).
The sampling frame for controls comprised all adult patients with previously untreated, smear-microscopy confirmed pulmonary drug-sensitive TB (referred to as drug-sensitive TB patients) diagnosed at the same THDs as cases. Patients were deemed to have drug-sensitive TB on the basis of a negative GeneXpert test result for rifampicin resistance and/or clinical response to first-line antimicrobial therapy during the first three months of treatment.
Exclusion criteria for both cases and controls were: age <18 years; known pregnancy at time of data collection; residence outside Yangon or in Yangon <3 months; and extrapulmonary TB only. Our selection strategy for cases and controls was devised after reviewing methods of other similar case-control studies (Hirpa et al. 2013 , Gomez-Gomez et al. 2015 .
All previously treated MDR-TB patients who met the eligibility criteria and consented to participate were included as cases. We recruited two controls per case from the same THD as the case. Each month we identified all patients meeting the eligibility criteria for controls, stratified them by THD of diagnosis, and then randomly selected a subset to include in the study as controls in order to achieve a 1:2 ratio of cases to controls. If a control patient could not be reached or refused to participate, he or she was replaced by another randomly selected control.
Data collection and management
A data collector fluent in Myanmar and trained to administer the questionnaire was assigned to each THD. Two structured questionnaires were used for data collection after piloting with the data collectors and study supervisor. The first extracted data from lab registers at the GeneXpert centres and townships labs, TB and MDR-TB registers at the THDs and patients' individual treatment cards. This included information on the patient's diagnosis and treatment, TB treatment history, side-effects and co-morbidities. Results of testing for HIV and diabetes were specifically extracted from THD records; when no tests had been conducted or recorded this was noted in the questionnaire. Smear microscopy grading of bacterial load in sputum was categorized using standard definitions (Lumb et al. 2013) .
The second questionnaire was used to collect primary data through face-to-face interviews with patients or in the case of death, a family member at patients' homes. Information was collected about the patient's socioeconomic status, symptoms, health-seeking behaviour, smoking status and alcohol consumption. Since data were collected 3 months after diagnosis, information about the adherence to medication and support received during the initial treatment period could be obtained. For cases, information about adherence and health-seeking behaviour during the current MDR-TB treatment and previous first-line TB treatment was collected. The data collector sought informed written consent prior to all participant interviews.
Data were collected using paper-based questionnaires. Paper questionnaires were manually checked at the local study office for accuracy and completion by the study supervisor and data was entered into Epidata (Version 3.1, The EpiData Association, Odense, Denmark). The Epidata file had built in checks to alert the data entry manager if out of range values were entered. Blinded double entry was conducted by the study supervisor on a monthly basis for 20% of all questionnaires (randomly selected). If any errors were identified, all questionnaires from the same data collector were checked and the data collector re-trained on the relevant questions if required.
Raw data were transferred to Stata (version 10, Stata Corporation, College Station, TX) for management and statistical analysis. Occupation was grouped into the following categories: dependent (no previous work or current work is unpaid, e.g. student or housewife), daily wage earner (paid for labour on daily basis), self-employed (e.g. street vendor, small business owner), private employee, government employee, unemployed (previously employed, but currently without work), retired and other. Education level was divided into four categories: primary school (grade 1-5), middle school (grade 6-9), high school (grade 10-11) and graduate, which included any form education taken after high school. The type of dwelling was divided into permanent (dwelling has a legal land title) or impermanent (dwelling does not have a land title).
Statistical analysis and power
We conducted an initial descriptive analysis to summarize characteristics of the study population. We then compared cases and controls using logistic regression models with MDR-TB as the outcome; odds ratios (ORs) we used to quantify the strength of association between potential risk factors and MDR-TB. We first performed a univariable logistic regression analysis to examine the effect of each variable of interest on the risk of MDR-TB. For demographic and socioeconomic factors, we then constructed multivariable models adjusting for two confounders identified a priori, age and sex. For factors related to patients' health status and behaviour, we constructed multivariable models adjusting only for age and sex, and models additionally adjusting for the following demographic/socioeconomic variables that showed a significant statistical association with MDR-TB in the univariable analysis (P < 0.1): religion, education and electricity and water supply in home. We additionally constructed multivariable models that accounted for potential clustering by township and found little difference in the model results. We thus present crude ORs from the univariable analysis and adjusted ORs from the multivariable analyses with corresponding 95% confidence intervals and two-tailed P-values for the Wald test.
Based on THD data from previous months, we estimated that $200 eligible MDR-TB patients could be recruited over a 6-7 -month study period, which was the maximum period available for data collection. The recruitment of 200 cases and twice as many controls provides over 90% power to detect a difference in private health provider use at 5% significance, assuming that 50% of controls and 65% of cases were treated for TB by private providers. Our estimates for private provider use are based on a study conducted by the Myanmar Medical Association in which $50% of patients stated that they visited a private doctor for symptoms that did not resolve with self-medication (Thet Naing Maung et al. 2008) .
Results
During the study period, 205 eligible MDR-TB patients (cases) were identified across the 10 THD sites, of which 3 refused to participate in the study. Our study therefore included 202 MDR-TB cases and 404 TB controls. Participant distribution by township and a summary of key characteristics is shown in Table 1 . The majority of patients were ethnically Bamar and Buddhist. Consistent with national notification figures and regional data, the number of men diagnosed was approximately double that of women. Between the time of diagnosis and interview ($3 months) 12 (5.9%) MDR-TB patients and 11 (2.7%) TB patients had died and a family member was interviewed instead of the patient.
Results from the analysis of demographic and socioeconomic factors influencing the risk of MDR-TB are summarised in Table 2 . The risk of MDR-TB was greater in patients with the highest level of education compared with patients that only had primary school education or less (aOR 1.78; 95% CI 1.01-3.13). There was also some evidence to suggest that higher socioeconomic status, as indicated by having both a water and electricity supply to the home, was associated with a higher risk of MDR-TB (aOR 1.99; 95% CI 1.09-3.63). While there were few patients belonging to religions other than Buddhism, the results indicate a 3-fold higher risk of MDR-TB among the small number of Christian patients studied. Socioeconomic and demographic factors investigated that did not have an association with MDR-TB in this study were: age, sex, years lived in Yangon, ethnicity, marital status, permanent/informal dwelling and monthly household income. Occupation was recorded during the interview, but was not included in the analysis, as it was not possible to ascertain whether occupation status changed owing to onset of disease (e.g. becoming unemployed or switching to informal employment).
Our analysis of factors related to patients' health status and behaviour (Table 3 ), indicated that patients with diabetes had a 2-fold greater risk of MDR-TB (aOR 2.10; 95% CI 1.17-3.76) compared with those without diabetes. Patients who reported missing TB treatment more than once a week also had a substantially greater risk of MDR-TB than those that reported never missing their medication (aOR 2.35; 95% CI 1.18-4.65). There was a weak association between having a treatment supporter during (previous) TB treatment and higher risk of MDR-TB (aOR 1.68; 95% CI 0.99-2.86). We also found some evidence to suggest that previous TB treatment at a private PSI-run SUN clinic was associated with MDR-TB (aOR 1.64; 95% CI 0.99-2.69). The following variables were not associated with MDR-TB in our study: smear-microscopy grading, selfreported drinking, self-reported smoking status and visiting a private doctor or traditional healer in the past two years.
Discussion
This study is the first to investigate patient and health system factors contributing to the high prevalence of MDR-TB in Myanmar, adding to the limited epidemiological evidence on drivers of the emergence of anti-TB drug resistance in low-resource Asian settings. The results indicate that patients who have diabetes, who miss taking their TB drugs more than once weekly and those with a higher socioeconomic or educational status were at a greater risk of developing MDR-TB.
In light of the challenges posed by MDR-TB in Myanmar, and the investment and reform ongoing to control the epidemic, this study provides critical information to help TB programmes and donors direct limited resources towards addressing risk factors for the emergence of drug resistance. By focusing on MDR-TB patients who had been previously treated for TB, we identified a number of factors that increase the risk of developing resistance to anti-TB drugs, many of which can be addressed by TB control programmes. Specifically, the study shows that TB patients who experience frequent, short interruptions in treatment-which is not routinely monitored by healthcare providers-and those with diabetes may require enhanced treatment support and monitoring by health services in order to prevent further generation of drug resistance.
A similar study on previously treated MDR-TB patients in Ethiopia found that incomplete first-line treatment (<8 months) was associated with a higher risk of developing MDR-TB (Hirpa et al. 2013) . This study provides new evidence that regular (more than weekly) interruption of treatment was associated with a higher risk of MDR-TB. This finding may have important implications for monitoring by TB control programmes, which is often set-up to identify longer interruptions in treatment. For example, based on WHO guidelines, TB control programmes define 'default from treatment' as a treatment interruption for at least two consecutive months (WHO 2011), whereas this study indicates that patients who have frequent short interruptions in first-line TB treatment are also at increased risk of acquired MDR-TB.
Consistent with our findings, other case-control studies conducted in Bangladesh, Iran and Mexico also reported an association between diabetes and increased risk of MDR-TB (Rifat et al. 2014; Gomez-Gomez et al. 2015; Perez-Navarro et al. 2015; Baghaei et al. 2016) . A systematic review found that diabetes is associated with an increased risk of failure and death during TB treatment, and there is some evidence linking poor response to TB treatment with impaired immunity in patients with diabetes (Fisher-Hoch et al. 2008; Baker et al. 2011) . There was, however, insufficient evidence for the review to draw strong conclusions about the association between diabetes and MDR-TB, and this study adds to the evidence base suggesting an increased risk of acquired resistance in TB patients with diabetes.
Having a treatment supporter during previous TB treatment was associated with a higher risk of MDR-TB, which has also been found in other studies (Hirpa et al. 2013) . This finding may occur because previously treated MDR-TB patients' most recent TB treatment would have likely been a retreatment regimen containing injectable streptomycin, which requires more supervised care (Hirpa et al. 2013; Rifat et al. 2015) .
There is mixed evidence from other studies on whether higher education and socioeconomic status are associated with a reduced or increased risk of MDR-TB. At least two other studies have found an increased risk of MDR-TB in patients with a higher level of education (Hirpa et al. 2013; Rifat et al. 2014) , and analyses in diverse settings have indicated a greater tendency for patients with higher education or wealth to use (unregulated) private practitioners (Makinen et al. 2000) . Other studies have found no association between socioeconomic status or education and MDR-TB (Brewer et al. 2011; Skrahina et al. 2013; Alikhanova et al. 2014; GomezGomez et al. 2015) and a study in Ethiopia found that lower education was associated with increased risk of MDR-TB (Mulisa et al. 2015) . While we found that one indicator of high socioeconomic status, having both a water and electricity supply to the home, was associated with a higher risk of MDR-TB, we did not find an association with other indicators, such as total household income, dwelling type or migrant status. Our findings thus also suggest that the relationship between socioeconomic factors in a transitioning health system is likely to be complex and context-specific.
Although this study was conducted in a very low-resource setting with only basic data management infrastructure, we were able to collect good quality primary data and extract data from paper records on numerous potential risk factors. However, we could not obtain reliable information on some potentially important risk factors such as HIV status, lung cavitation, employment at the time of infection and smoking and alcohol consumption at the time of disease occurrence. Since records of MDR-TB cases were not linked to medical records from the patients' previous TB treatment, we were not able to assess disease severity or side-effects during first-line treatment. We also had to rely on self-reporting of adherence and health-seeking behaviour, owing to which some variables may suffer from recall or reporting bias. As with most other case-control studies on MDR-TB, collecting data about genetics of the infecting bacterial strain was beyond the scope of this study (Caminero 2010; Hirpa et al. 2013) . We recognize that we therefore cannot rule out the possibility that some previously treated MDR-TB patients may have been re-infected with the drug-resistant strain rather than acquiring resistance during the course of their first-line treatment. Genetics of the infecting bacterial strain and the host may be important to investigate in future studies in this region, but such studies require considerable infrastructure and funding to initiate. Similarly, we acknowledge that some of the controls in this study who did not have any evidence of resistance to anti-TB drugs may go on to develop drug resistance in the future (Driver et al. 2001) . Since the primary diagnostic test was Xpert/RIF, which only detects resistance to one drug, rifampicin, patients carrying strains resistant to other anti-TB drugs without rifampicin resistance would not have been included as cases. Similarly, MDR-TB patients infected with bacterial strains resistant to drugs beyond rifampicin and isoniazid (including those with XDR-TB) would have not been identified owing to limitations in availability of diagnostics; this group would have been included among the cases. Finally, it should be considered that controls were defined as patients who were positive on smear-microscopy, whereas cases (MDR-TB patients) were diagnosed using GeneXpert; one difference between cases and controls is therefore that some cases were negative on smear-microscopy, whereas no smear-negative controls would be included. Since only 16% of MDR-TB cases in our study were smear-negative (but GeneXpert positive), the potential bias introduced by the exclusion of smear-negative TB patients in the control group was limited, as confirmed by a sensitivity analysis conducted by excluding smear-negative MDR-TB patients. Including smearnegative patients as controls, on the other hand, may have raised concerns about whether these patients truly had TB given the challenges diagnosing smear-negative TB based on clinical and radiological findings in low-resource settings (Harries et al. 1998) .
Our findings have potentially important programmatic implications for TB control in low-resource settings. While it is important to continue focussing on prevention of long interruptions in firstline TB treatment, our study indicates that identification of patients who regularly have short interruptions in anti-TB medication should also be given attention. Such patients, who were found to have a higher risk of developing MDR-TB in this study, could be provided with additional support during the course of treatment in order to ensure optimal treatment outcomes (Baral et al. 2014) .
In Myanmar, large investments for scale-up of MDR-TB treatment are being made rapidly (Myint 2015) , and guidelines for prioritizing patients for GeneXpert screening are being formulated based on evidence of risk factors for MDR-TB (WHO 2013); results of this study indicate that diabetes may be an important additional factor to consider. The potential effectiveness and costeffectiveness of GeneXpert screening in this setting and elsewhere are, however, unknown, as is the wider impact on the management of primary TB. It is essential that expansion of MDR-TB management does not detract from strengthening primary TB services, which are essential for preventing acquired MDR-TB (Khan and Coker 2014) .
Conclusions
MDR-TB, which is difficult and expensive to diagnose and treat, is the optimal strategy from a patient and health system perspective, particularly in low-resource settings. Evidence on risk factors driving the generation of acquired MDR-TB, as provided by this study, and on sustainable, scalable interventions that can be applied in low-income settings is essential for TB programmes and donors to effectively allocate limited resources to maximise impact on population health.
Ethical approval
Ethical clearance was gained from LSHTM Research Ethics Committee, the FHI 360 Protection of Human Subjects Committee and locally, through the Myanmar Ministry of Health. Written consent was obtained from all participants. 
